Ocular hypotensive effect of oral palmitoyl-ethanolamide: a clinical trial
Randomised controlled trialHumans
- Design
- Randomised controlled trial
- Subjects
- 42 patients with primary open-angle glaucoma or ocular hypertension already on timolol 0.5 percent, with pressure 19 to 24 mmHg
- Dose used in the study
- PEA 300 mg tablets twice daily or vehicle placebo, added to timolol
- Duration
- 2 months, 2-month washout, then 1 month on the other treatment (crossover)
- What was measured
- Intraocular pressure, best-corrected visual acuity and visual field.
What the authors reported
This trial found:
- On PEA, pressure fell by 3.2 mmHg at 1 month and 3.5 mmHg (15.9 percent) at 2 months from a baseline of 21.6.
- On placebo it fell by 0.4 and 0.3 mmHg (p < 0.001 versus PEA).
- There were no changes in vital signs, visual field or acuity, and no adverse events.
Limits of this study
A randomised, double-blind crossover trial of 42 patients. All patients were also on timolol, so the result is for PEA as an add-on. The second crossover period was 1 month, shorter than the first. Registered UMIN000002833. Funding not stated in the abstract.
Source
PubMed 21705689 · doi:10.1167/iovs.10-7057
Entry checked against the abstract, supplied by Devlin on 2026-10-19. The dose shown is the dose the researchers used. It is not a recommendation. How to read this page.